Research programme: apoptosis inducers - GPC Biotech
Latest Information Update: 14 Mar 2008
At a glance
- Originator GPC Biotech AG
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jun 2005 This programme is still in active development
- 04 Sep 2003 This programme is still in active development
- 30 Jan 2001 Preclinical development for Cancer in Germany (Unknown route)